A personal health crisis, a growing portfolio of patents and a global wellness business come together in Christina Rahm’s story.
Since 2021 she has been granted at least four U.S. patents as the sole inventor, with more applications moving through different stages of review according to United States Patent and Trademark Office records. Her company DRC Ventures runs manufacturing facilities in several states, and her products now reach customers in 89 countries through The ROOT Brands, a distribution and direct selling company that has expanded quickly since it launched in 2020.
Rahm’s path did not start in a lab. It began in hospital rooms where she faced what she describes as life threatening diagnoses, including Lyme disease, cancer and a brain tumor. Out of that period came a long, self directed research effort that took her from being a patient to becoming an inventor and raised broader questions about how personal experience can influence scientific innovation.
When Medicine Couldn’t Provide Answers…
Rahm’s health problems began in college with symptoms that doctors struggled to diagnose correctly. Working as a hotel maid to support herself, she experienced debilitating fatigue and pain that many physicians attributed to stress or other factors. She was eventually diagnosed with Lyme disease, and before age 25 faced additional serious health challenges.
Traditional treatments provided only limited relief, and Rahm began exploring alternative approaches. She focused particularly on environmental factors like mold exposure, heavy metals, and other toxins that she believed conventional medicine was overlooking. This led her to spend thousands of hours studying cellular biology, plant-based compounds, and detoxification mechanisms without formal graduate education in these fields.
In the Say It Skillfully podcast, Rahm explained that she understood one doctor was not going to determine her life. She described her lifelong mission as solving problems and helping others, a drive that began in childhood.
These claims and the broader concept of “detoxification” sit within a longstanding cultural contradiction: the gap between what patients believe they should do when they feel traditional medicine has failed them, and what evidence-based medicine can confirm.
The National Institutes of Health (NIH) notes that scientific evidence for the effectiveness of commercial detox products remains limited. “In 2015, a team of experts concluded that results so far don’t support the use of detox diets for weight loss or removing toxins,” according to NIH News in Health.
Rahm’s granted USPTO patents represent a real achievement that goes beyond their number. The patent prosecution process is one of the most rigorous gatekeeping mechanisms in intellectual property, requiring what the USPTO describes as “knowledge of patent law, rules and practices of the United States Patent and Trademark Office, as well as knowledge in scientific or technical matters.” The patents granted to Rahm span multiple categories of formulations and methods. For example:
Clinoptilolite/zeolite-based formulations: One patent describes methods designed to convert clinoptilolite (a naturally occurring zeolite) into a water-soluble form that, as described, binds with heavy metals and other substances.
Permeable substrate applications: Another patent describes permeable substrates containing minerals and formulas for use in textiles and environments described as highly toxic or clinical settings.
Tryptophan-based compositions: A separate patent describes compositions related to sleep and circadian rhythm disruption.
Alcohol metabolism acceleration formulations: Another describes formulations designed to accelerate alcohol metabolism using a combination of ingredients.
Empirical research shows that getting a U.S. patent is far from routine. In a large-scale study published in the Yale Journal of Law & Technology, economists Michael D. Carley, Deepak Hegde, and Alan C. Marco found that only 11.4% of U.S. patent applications were approved at the first substantive examination stage. (Carley, Hegde, and Marco, “What Is the Probability of Receiving a US Patent?”, Yale Journal of Law & Technology, Vol. 17, 2015)
Most applicants face at least one rejection and lengthy negotiations with the USPTO before receiving a patent. For inventions at the nanoscale level, the situation is even more complex. In U.S. patent practice, lawyers view such inventions as presenting unique challenges in terms of clear definition and consistent scope of claims, partly because the concept of “nanotechnology” itself can be defined inconsistently and measurement can be difficult in practice.
Professor Jordan Paradise of Seton Hall University School of Law notes that in the nanotechnology field, patentability is more often confirmed when an application goes beyond simple differences in scale and clearly describes a novel application and utility while meeting other patent law requirements. In Rahm’s case, the granting of patents for water-soluble clinoptilolite fragments and permeable substrates indicates that USPTO examiners considered the claimed solutions to extend beyond simple “miniaturization.” In other words, Rahm’s solutions successfully demonstrated novel utility beyond mere scale reduction.
Despite scientific questions about detoxification products, Rahm has built significant manufacturing infrastructure. Her recent $4.2 million investment in Xoted Biotechnology Labs in Spartanburg County, South Carolina, created 34 jobs focused on plant-based research, seed research, oil refining, and textile applications. She serves as Chief Operating Officer at Strata Biotech in Nevada, a GMP-certified facility specializing in precision medicine and cellular regeneration.
Spartanburg County Councilman David Britt praised the economic impact: “The research and development hub and the sheer volume of proprietary manufacturing processes that Xoted is bringing to Spartanburg County is a win for the entire state of South Carolina. Biotechnology has been called the next frontier, and we are glad to partner with a company that is at the forefront of this space.”
DRC Ventures claims more than 200 trademarked manufacturing processes, according to a May 2025 GSA Business Report article.
Rahm’s success as a woman patent holder does illuminate real disparities in the patent system. USPTO data confirms that only about 13% of patent holders are women, reflecting both inequality and potential lost innovation.
Rahm maintains her health in what she describes as remission, using the detoxification protocols and cellular support systems she developed. She frames her work through a holistic philosophy: “We are connected to everything around us, from a leaf on a tree to the genetic code within ourselves. That belief is what drives our innovation.”
Her vision includes licensing opportunities for broader distribution, ongoing research, and additional patents in development. For consumers, the fundamental challenge remains: distinguishing innovative solutions from wellness industry marketing requires evidence that patents alone cannot provide. Rahm’s path from diagnosis to discovery reflects both the promise and complexity of innovation.
